title: Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis.
authors.affiliation: University of Washington Medical Center, Seattle, Wash; Center for Allergy and Inflammation, UW Medicine at South Lake Union, Seattle, Wash. Electronic address: maltman@uw.edu.
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Altman
authors.affiliation: University of Washington Medical Center, Seattle, Wash.
authors.forename: Jake
authors.initials: J
authors.lastname: Lenington
authors.affiliation: University of Washington Medical Center, Seattle, Wash.
authors.forename: Steve
authors.initials: S
authors.lastname: Bronson
authors.affiliation: University of Washington Medical Center, Seattle, Wash; Center for Allergy and Inflammation, UW Medicine at South Lake Union, Seattle, Wash.
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Ayars
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000276:immunology*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D000069444:Omalizumab / Q000627:therapeutic use*; D012008:Recurrence; D012131:Respiratory Insufficiency
chemical_list: D000305:Adrenal Cortex Hormones; D018926:Anti-Allergic Agents; D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000069444:Omalizumab; C434107:mepolizumab